A systematic review and meta-analysis of plasma amyloid 1-42 and tau as biomarkers for Alzheimer’s disease
Objective: Amyloid 1-42 (Aβ42) and tau in cerebrospinal fluid are currently used as markers for diagnosis of Alzheimer’s disease. Conflicting reports exist regarding their plasma levels in Alzheimer’s disease patients. A meta-analysis was performed to statistically validate the use of plasma Aβ42 an...
Main Authors: | Keerthanaa Balasubramanian Shanthi, Sreeram Krishnan, P Rani |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2015-08-01
|
Series: | SAGE Open Medicine |
Online Access: | https://doi.org/10.1177/2050312115598250 |
Similar Items
-
Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer’s disease
by: Fernando Gonzalez-Ortiz, et al.
Published: (2024-04-01) -
Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease
by: Carla M. Startin, et al.
Published: (2019-03-01) -
Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain
by: Tapiola, T, et al.
Published: (2009) -
Diagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers
by: Jinny Claire Lee, et al.
Published: (2019-05-01) -
Cerebrospinal fluid amyloid beta and tau protein: Biomarkers for Alzheimer's disease
by: Mandić Gorana, et al.
Published: (2008-01-01)